

Raymond Schuch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9252072/publications.pdf>

Version: 2024-02-01

59
papers

3,536
citations

172457

29
h-index

138484

58
g-index

61
all docs

61
docs citations

61
times ranked

3132
citing authors

#	ARTICLE	IF	CITATIONS
1	A bacteriolytic agent that detects and kills <i>Bacillus anthracis</i> . <i>Nature</i> , 2002, 418, 884-889.	27.8	585
2	Novel Phage Lysin Capable of Killing the Multidrug-Resistant Gram-Negative Bacterium <i>Acinetobacter baumannii</i> in a Mouse Bacteremia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1983-1991.	3.2	214
3	PlyC: A multimeric bacteriophage lysin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 10765-10770.	7.1	197
4	Identification of a Broadly Active Phage Lytic Enzyme with Lethal Activity against Antibiotic-Resistant <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> . <i>Journal of Bacteriology</i> , 2004, 186, 4808-4812.	2.2	196
5	Combination Therapy With Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant <i>Staphylococcus aureus</i> -Induced Murine Bacteremia. <i>Journal of Infectious Diseases</i> , 2014, 209, 1469-1478.	4.0	165
6	Lysins: the arrival of pathogen-directed anti-infectives. <i>Journal of Medical Microbiology</i> , 2013, 62, 1506-1516.	1.8	162
7	Reinventing phage therapy: are the parts greater than the sum?. <i>Nature Biotechnology</i> , 2006, 24, 1508-1511.	17.5	154
8	The Secret Life of the Anthrax Agent <i>Bacillus anthracis</i> : Bacteriophage-Mediated Ecological Adaptations. <i>PLoS ONE</i> , 2009, 4, e6532.	2.5	144
9	Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	122
10	Detailed Genomic Analysis of the ϕ W12 and ϕ 3 Phages Infecting <i>Bacillus anthracis</i> : Implications for Evolution of Environmental Fitness and Antibiotic Resistance. <i>Journal of Bacteriology</i> , 2006, 188, 3037-3051.	2.2	99
11	A system for identifying post-invasion functions of invasion genes: requirements for the Mxi-Spa type III secretion pathway of <i>Shigella flexneri</i> in intercellular dissemination. <i>Molecular Microbiology</i> , 1999, 34, 675-689.	2.5	94
12	MxiE Regulates Intracellular Expression of Factors Secreted by the <i>Shigella flexneri</i> 2a Type III Secretion System. <i>Journal of Bacteriology</i> , 2002, 184, 4409-4419.	2.2	83
13	The 1.6Å Crystal Structure of the Catalytic Domain of PlyB, a Bacteriophage Lysin Active Against <i>Bacillus anthracis</i> . <i>Journal of Molecular Biology</i> , 2007, 366, 540-550.	4.2	81
14	Exebacase for patients with <i>Staphylococcus aureus</i> bloodstream infection and endocarditis. <i>Journal of Clinical Investigation</i> , 2020, 130, 3750-3760.	8.2	78
15	MxiM and MxiJ, Base Elements of the Mxi-Spa Type III Secretion System of <i>Shigella</i> , Interact with and Stabilize the MxiD Secretin in the Cell Envelope. <i>Journal of Bacteriology</i> , 2001, 183, 6991-6998.	2.2	75
16	PlyPH, a Bacteriolytic Enzyme with a Broad pH Range of Activity and Lytic Action against <i>Bacillus anthracis</i> . <i>Journal of Bacteriology</i> , 2006, 188, 2711-2714.	2.2	74
17	nadA and nadB of <i>Shigella flexneri</i> 5a are antivirulence loci responsible for the synthesis of quinolinate, a small molecule inhibitor of <i>Shigella</i> pathogenicity. <i>Microbiology (United Kingdom)</i> , 2007, 153, 2363-2372.	1.8	71
18	Development of a high throughput assay for indirectly measuring phage growth using the OmniLog TM system. <i>Bacteriophage</i> , 2012, 2, 159-167.	1.9	71

#	ARTICLE	IF	CITATIONS
19	Lysocins: Bioengineered Antimicrobials That Deliver Lysins across the Outer Membrane of Gram-Negative Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	62
20	Cell wall hydrolases and antibiotics: exploiting synergy to create efficacious new antimicrobial treatments. <i>Current Opinion in Microbiology</i> , 2016, 33, 18-24.	5.1	56
21	Genomic Sequence of C 1 , the First Streptococcal Phage. <i>Journal of Bacteriology</i> , 2003, 185, 3325-3332.	2.2	51
22	The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteriolysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	51
23	Beyond the Chromosome: The Prevalence of Unique Extra-Chromosomal Bacteriophages with Integrated Virulence Genes in Pathogenic <i>Staphylococcus aureus</i> . <i>PLoS ONE</i> , 2014, 9, e100502.	2.5	48
24	Anthrax SET Protein. <i>Journal of Biological Chemistry</i> , 2013, 288, 23458-23472.	3.4	44
25	Use of a Bacteriophage Lysin to Identify a Novel Target for Antimicrobial Development. <i>PLoS ONE</i> , 2013, 8, e60754.	2.5	41
26	Identifying Active Phage Lysins through Functional Viral Metagenomics. <i>Applied and Environmental Microbiology</i> , 2010, 76, 7181-7187.	3.1	36
27	A structural basis for the allosteric regulation of non-hydrolysing UDP-GlcNAc 2-epimerases. <i>EMBO Reports</i> , 2008, 9, 199-205.	4.5	35
28	Exebacase Demonstrates <i>In Vitro</i> Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	33
29	A Novel Spore Protein, ExsM, Regulates Formation of the Exosporium in <i>Bacillus cereus</i> and <i>Bacillus anthracis</i> and Affects Spore Size and Shape. <i>Journal of Bacteriology</i> , 2010, 192, 4012-4021.	2.2	32
30	Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	32
31	Genetic Structure of the nadA and nadB Antivirulence Loci in <i>Shigella</i> spp. <i>Journal of Bacteriology</i> , 2007, 189, 6482-6486.	2.2	29
32	Rapid DNA Library Construction for Functional Genomic and Metagenomic Screening. <i>Applied and Environmental Microbiology</i> , 2008, 74, 1649-1652.	3.1	29
33	Spa33, a Cell Surface-Associated Subunit of the Mxi-Spa Type III Secretory Pathway of <i>Shigella flexneri</i> , Regulates Ipa Protein Traffic. <i>Infection and Immunity</i> , 2001, 69, 2180-2189.	2.2	28
34	Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant <i>Staphylococcus aureus</i> Osteomyelitis in Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	23
35	The PlyB Endolysin of Bacteriophage vB_BanS_Bcp1 Exhibits Broad-Spectrum Bactericidal Activity against <i>Bacillus cereus</i> Sensu Lato Isolates. <i>Applied and Environmental Microbiology</i> , 2019, 85, .	3.1	22
36	A Genetic Screen to Identify Bacteriophage Lysins. <i>Methods in Molecular Biology</i> , 2009, 502, 307-319.	0.9	22

#	ARTICLE	IF	CITATIONS
37	Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	21
38	Identification of a Ligand on the Wip1 Bacteriophage Highly Specific for a Receptor on <i>Bacillus anthracis</i> . <i>Journal of Bacteriology</i> , 2013, 195, 4355-4364.	2.2	18
39	Novel Algorithms Reveal Streptococcal Transcriptomes and Clues about Undefined Genes. <i>PLoS Computational Biology</i> , 2007, 3, e132.	3.2	14
40	Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant <i>Staphylococcus aureus</i> Endocarditis as Determined by Echocardiography. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	14
41	Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance. <i>Frontiers in Microbiology</i> , 2022, 13, 841905.	3.5	14
42	Discovery of Novel Putative Inhibitors of UDP-GlcNAc 2-Epimerase as Potent Antibacterial Agents. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1142-1147.	2.8	13
43	Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against <i>Staphylococcus aureus</i> in a Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	13
44	Complete Genome Sequence of <i>Bacillus cereus</i> <i>Sensu Lato</i> Bacteriophage Bcp1. <i>Genome Announcements</i> , 2014, 2, .	0.8	12
45	In vitro activity of Exebacase (CF-301) against clinical <i>Staphylococcus aureus</i> surveillance isolates from the United States, Europe, and Latin America, 2015-2017. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 95, 114879.	1.8	10
46	Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0311720.	3.9	10
47	The Mxi-Spa Type III Secretory Pathway of <i>Shigella flexneri</i> Requires an Outer Membrane Lipoprotein, MxiM, for Invasin Translocation. <i>Infection and Immunity</i> , 1999, 67, 1982-1991.	2.2	10
48	Crowd control: <i>Bacillus anthracis</i> and quorum sensing. <i>Virulence</i> , 2010, 1, 57-59.	4.4	6
49	Isolation of Bacteriophages from Environmental Sources, and Creation and Functional Screening of Phage DNA Libraries. <i>Current Protocols in Essential Laboratory Techniques</i> , 2013, 7, 13.3.1.	2.6	6
50	Isolation, Culture, and Characterization of Bacteriophages. <i>Current Protocols in Essential Laboratory Techniques</i> , 2013, 7, 4.4.1.	2.6	6
51	Exebacase in Addition to Daptomycin against MRSA. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0012821.	3.2	6
52	Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal <i>Staphylococcus aureus</i> Lung Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0272320.	3.2	6
53	Development of a Broth Microdilution Method for Exebacase Susceptibility Testing. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0258720.	3.2	5
54	Activity of Exebacase (CF-301) against Biofilms Formed by <i>Staphylococcus epidermidis</i> Strains Isolated from Prosthetic Joint Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.2	4

#	ARTICLE	IF	CITATIONS
55	Activity of Lysin CF-296 Alone and in Addition to Daptomycin in a Rat Model of Experimental Methicillin-Resistant Staphylococcus aureus Osteomyelitis. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	3
56	Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against Staphylococcus aureus in the murine thigh infection model. Journal of Antimicrobial Chemotherapy, 2021, 76, 2622-2628.	3.0	2
57	Lysin CF-301 Demonstrates In Vitro Synergy with Conventional Antibiotics against Staphylococcus aureus. Open Forum Infectious Diseases, 2017, 4, S370-S370.	0.9	1
58	1550. PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models. Open Forum Infectious Diseases, 2019, 6, S565-S566.	0.9	1
59	712. Activity of Exebacase (CF-301) Against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms on Orthopedic Kirschner Wires. Open Forum Infectious Diseases, 2019, 6, S320-S320.	0.9	1